Evidence map›Paper›PMID 41816431›Full record

ArticleJournal of thoracic disease2026

Role of

Aidiye Tiliwalidi, Jingkun Liu, Nueramina Kadierjiang, Yiliyaer Nuerrula, Ruonan Cai, Subinuer Yizihaer, Mayinur Eli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aidiye TiliwalidiDepartment of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jingkun LiuDepartment of Thoracic and Abdominal Radiotherapy, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Nueramina KadierjiangDepartment of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yiliyaer NuerrulaDepartment of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Ruonan CaiDepartment of Hematology and Oncology, Karamay Central Hospital of Xinjiang, Karamay, China.
Subinuer YizihaerDepartment of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Mayinur EliDepartment of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The role of F-box and WD repeat domain-containing protein 7 (FBXW7) in cancer remains controversial, as it has been reported to function as either a tumor suppressor or an oncogene depending on tumor type. This study was designed to investigate the role of Methods: FBXW7 protein expression was examined by immunohistochemistry in ESCC tissues and matched adjacent nontumor tissues from 69 ESCC patients. The functional effects of Results: FBXW7 protein was significantly upregulated in ESCC tissues compared to adjacent nontumor tissues. FBXW7 upregulation was significantly associated with poor differentiation, deeper tumor invasion, and the presence of lymph node metastasis. Conclusions:

Indexed as

esophageal squamous cell carcinoma (ESCC)F-box and WD repeat domain-containing protein 7 (FBXW7)knockdownoverexpressiontumor-promoting effect

Identifiers

PMID41816431
PMCPMC12972801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.